Streetbeat News

Revenues

TJX

TJX Companies reported Q4 2024 earnings per share of $1.12, meeting analyst expectations, and sales of $16.40 billion, exceeding the $16.21 billion estimate. This represents a 12.95% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:31 pm

LTH

Life Time Group (LTH) projects its 2024 revenue to be between $2.46B and $2.5B, aligning with the $2.46B consensus. The company also forecasts an adjusted EBITDA of $595M to $610M. These projections represent an approximate 11.9% increase in revenue and a 12.2% increase in adjusted EBITDA from 2023. Additionally, LTH aims to reduce its net debt leverage ratio to 3.0x by the end of 2024, become free cash flow positive in Q2 2024, open 9-10 new centers, and expects to leverage net operating loss carryforwards from the COVID-19 pandemic to offset a significant portion of its 2024 cash taxes.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:20 pm

LTH

Life Time Group (LTH) projects Q1 2024 revenue to be between $585M-$595M, surpassing the consensus estimate of $572.86M. The company also expects net income to range from $29M-$32M. These forecasts represent significant increases over the previous year, with revenue, net income, and adjusted EBITDA expected to grow by 15.5%, 10.9%, and 19.9% respectively.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:19 pm

BRKR

Bruker Corporation (BRKR) has signed a share purchase agreement to acquire ELITechGroup, a molecular diagnostics company, for €870 million in cash, excluding ELITech's Clinical Chemistry business. The deal, disclosed in an 8-K SEC filing on December 26, 2023, follows a put option agreement with the sellers, pending consultations in France and The Netherlands. Bruker anticipates completing the acquisition in Q2 2024. ELITechGroup, minus the clinical chemistry segment, reported revenues of approximately €150 million in 2023.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:18 pm

JBI

Janus projects its FY24 revenue to be between $1.092 billion and $1.125 billion, slightly below the analyst estimate of $1.13 billion.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:16 pm

INVZ

Innoviz Technologies has set its Q1 2024 revenue expectations to $5-$6 million, a significant increase from previous years, aiming for a 395-494% YoY growth. The company plans to secure 2-3 additional customer programs and $20-70 million in new NRE bookings for 2024. This shift to quarterly revenue guidance comes after a cautious approach to 2023 revenue targets, with the company believing this method offers more accuracy.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:14 pm

AVDX

AvidXchange projects its FY24 revenue to be in the range of $441M-$447M, which is around the analyst estimate of $444.3M.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:14 pm

HCM

HUTCHMED projects its full year 2024 Oncology/Immunology consolidated revenue to be between $300 million and $400 million. This forecast is based on an anticipated 30% to 50% growth in revenue from marketed oncology products.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:13 pm

VLN

Valens Semiconductor projects Q1 2024 revenue to be between $11M-$11.2M, below the $12.08M estimate, citing challenging macroeconomic conditions and shorter lead times affecting the semiconductor industry. Gross margin is expected to be 52.2%-53.0%, with an adjusted EBITDA loss of $(9.7)M-$(9.1)M.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:10 pm

FOLD

Amicus Therapeutics forecasts an 11-16% revenue growth for Galafold in 2024 at constant exchange rates (CER) and expects to achieve full-year non-GAAP profitability in the same year.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 12:07 pm